The FDA has approved vonoprazan (Voquezna, Phathom) 10-mg tablets for use in patients with nonerosive reflux disease.
This new approval joins prior approvals for the potassium-competitive acid blocker for erosive esophagitis and for Helicobacter pylori eradication when used in combination with antibiotics.
The approval for use in patients with NERD follows positive results from the phase 3 PHALCON-NERD-301 trial (Clin Gastroenterol Hepatol 2024 May 14. doi:10.1016/j.cgh.2024.05.004). In the